A systematic review of the health economic consequences of quadrivalent influenza vaccination

References

• World Health Organization. Influenza (seasonal) [Internet]. 2014. Available from: http://www.who.int/mediacentre/factsheets/fs211/en/.
   Google Scholar
• Molinari NM, Ortega-Sanchez IR, Messonnier ML, et al. The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine. 2007;25:5086–5096.
   PubMed Web of Science ®Google Scholar
• Ambrose CS, Levin MJ. The rationale for quadrivalent influenza vaccines. Hum Vaccin Immunother. 2012;8(1):81–88.
   PubMed Web of Science ®Google Scholar
• Caini S, Huang QS, Ciblak MA, et al. Epidemiological and virological characteristics of influenza B: results of the global influenza B study. Influenza Other Respir Viruses. 2015;9:3–12.
   Google Scholar
• Caini S, Andrade W, Badur S, et al. Temporal patterns of influenza A and B in tropical and temperate countries: what are the lessons for influenza vaccination? Plos One. 2016;11(3):1–15.
   Web of Science ®Google Scholar
• US Food and Drug Administration. FDA approves first quadrivalent vaccine to prevent seasonal influenza. 2012. http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm294057.htm
   Google Scholar
• Grohskopf LA, Sokolow LZ, Broder KR, et al. Prevention and control of seasonal influenza with vaccines. Recommendations of the advisory committee on immunization practices — United States, 2016–17 influenza season. Mmwr. 2016;65(5):1–54.
   PubMedGoogle Scholar
• National Advisory Committee on Immunization (NACI). Canadian immunization guide chapter on influenza and statement on seasonal influenza vaccine for 2016-2017 [Internet]. (2016). Available from: http://www.phac-aspc.gc.ca/naci-ccni/flu-2016-grippe-eng.php#footnote74.
   Google Scholar
• Immunise Australia Program. Influenza (flu) [Internet]. (2016). Available from: http://www.immunise.health.gov.au/internet/immunise/publishing.nsf/content/immunise-influenza.
   Google Scholar
• Public Health England. Flu plan Winter 2016/17 [Internet]. London Available from: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/525967/Annual_flu_plan_2016_to_2017.pdf.
   Google Scholar
• European Centre for Disease Prevention and Control. Influenza vaccination [Internet]. (2016). Available from: http://ecdc.europa.eu/en/healthtopics/seasonal_influenza/vaccines/Pages/influenza_vaccination.aspx.
   Google Scholar
• Takla A, Wichmann O, Carrillo-Santisteve P, et al. Characteristics and practices of National Immunisation Technical Advisory Groups in Europe and potential for collaboration, April 2014. Eurosurveillance. 2015;20:9.
   Web of Science ®Google Scholar
• Quinn E, Jit M, Newall AT. Key issues and challenges in estimating the impact and cost-effectiveness of quadrivalent influenza vaccination. Expert Rev Pharmacoecon Outcomes Res. 2014;14(3):425–435.
   PubMed Web of Science ®Google Scholar
• Tisa V, Barberis I, Faccio V, et al. Quadrivalent influenza vaccine: a new opportunity to reduce the influenza burden. J Prev Med Hyg. 2016;57:28–33.
   PubMedGoogle Scholar
• Husereau D, Drummond M, Petrou S, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. Pharmacoeconomics. 2013;31:361–367.
   PubMed Web of Science ®Google Scholar
• Vemer P, Corro Ramos I, van Voorn GAK, et al. AdViSHE: a validation-assessment tool of health-economic models for decision makers and model users. Pharmacoeconomics. 2016;34(4):349–361.
   PubMed Web of Science ®Google Scholar
• Organisation for Economic Co-operation and Development. Consumer prices. http://stats.oecd.org/Index.aspx?querytype=view&queryname=221#. (2017).
   Google Scholar
• Organisation for Economic Co-Operation and Development. PPPs and exchange rates. 2017 http://stats.oecd.org/Index.aspx?datasetcode=SNA_TABLE4
   Google Scholar
• Moher D, Liberati A, Tetzlaff J, et al., PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Plos Med [Internet]. 2009;6(7):e1000097. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19621072
   PubMed Web of Science ®Google Scholar
• Chit A, Roiz J, Aballea S. An assessment of the expected cost-effectiveness of quadrivalent influenza vaccines in Ontario, Canada using a static model. Plos One. 2015;10(7):1–15.
   Web of Science ®Google Scholar
• Chit A, Roiz J, Briquet B, et al. Expected cost effectiveness of high-dose trivalent influenza vaccine in US seniors. Vaccine. 2015;33(5):734–741.
   PubMed Web of Science ®Google Scholar
• Clements KM, Meier G, McGarry LJ, et al. Cost-effectiveness analysis of universal influenza vaccination with quadrivalent inactivated vaccine in the United States. Hum Vaccines Immunother. 2014;10(5):1171–1180.
   PubMed Web of Science ®Google Scholar
• De Boer PT, Crépey P, Pitman RJ, et al. Cost-effectiveness of quadrivalent versus trivalent influenza vaccine in the United States. Value Heal. 2016;19(8):964–975.
   PubMed Web of Science ®Google Scholar
• Dolk C, Eichner M, Welte R, et al. Cost-utility of quadrivalent versus trivalent influenza vaccine in Germany, using an individual-based dynamic transmission model. Pharmacoeconomics. 2016;34(12):1299–1308.
   PubMed Web of Science ®Google Scholar
• García A, Lejarazu R, Reina J, et al. Cost–effectiveness analysis of quadrivalent influenza vaccine in Spain. Hum Vaccin Immunother. 2016;12(9):2269–2277.
   PubMed Web of Science ®Google Scholar
• Jamotte A, Chong CF, Manton A, et al. Impact of quadrivalent influenza vaccine on public health and influenza-related costs in Australia. BMC Public Health. 2016;16(1):630.
   PubMed Web of Science ®Google Scholar
• Lee BY, Bartsch SM, Willig AM. The economic value of a quadrivalent versus trivalent influenza vaccine. Vaccine. 2012;30(52):7443–7446.
   Google Scholar
• Meier G, Gregg M, Poulsen Nautrup B. Cost-effectiveness analysis of quadrivalent influenza vaccination in at-risk adults and the elderly: an updated analysis in the UK. J Med Econ. 2015;18(9):746–761.
   PubMed Web of Science ®Google Scholar
• Mullikin M, Tan L, Jansen JP, et al. A novel dynamic model for health economic analysis of influenza vaccination in the elderly. Infect Dis Ther. 2015;4(4):459–487.
   PubMedGoogle Scholar
• Nagy L, Heikkinen T, Sackeyfio A, et al. The clinical impact and cost effectiveness of quadrivalent versus trivalent influenza vaccination in Finland. Pharmacoeconomics. 2016;34(9):939–951.
   PubMed Web of Science ®Google Scholar
• Thommes EW, Ismaila A, Chit A, et al. Cost-effectiveness evaluation of quadrivalent influenza vaccines for seasonal influenza prevention: a dynamic modeling study of Canada and the United Kingdom. BMC Infect Dis. 2015;15:465.
   PubMed Web of Science ®Google Scholar
• Uhart M, Clay E, Largeron N. Public health and economic impact of seasonal influenza vaccination with quadrivalent influenza vaccines compared to trivalent influenza vaccines in Europe. Hum Vaccin Immunother. 2016;12(9):2259–2268.
   PubMed Web of Science ®Google Scholar
• Van Bellinghen LA, Meier G, Van Vlaenderen I. The potential cost-effectiveness of quadrivalent versus trivalent influenza vaccine in elderly people and clinical risk groups in the UK: a lifetime multi-cohort model. Plos One. 2014;9:6.
   Web of Science ®Google Scholar
• You JH, Ming WK, Chan PK. Cost-effectiveness analysis of quadrivalent influenza vaccine versus trivalent influenza vaccine for elderly in Hong Kong. BMC Infect Dis. 2014;14:618.
   PubMed Web of Science ®Google Scholar
• You JHS, Ming WK, Chan PKS. Cost-effectiveness of quadrivalent influenza vaccine in Hong Kong - a decision analysis. Hum Vaccines Immunother. 2015;11(3):564–571.
   PubMed Web of Science ®Google Scholar
• Lee BY, Bartsch SM, Willig AM. Corrigendum to “The economic value of a quadrivalent versus trivalent influenza vaccine.” Vaccine. 2013;31:2477–2479.
   Web of Science ®Google Scholar
• Crépey P, De Boer PT, Postma MJ. Retrospective public health impact of a quadrivalent influenza vaccine in the United States. Influenza Other Respi Viruses. 2015;9(Suppl 1):39–46.
   PubMed Web of Science ®Google Scholar
• Thommes EW, Chit A, Meier GC, et al. Examining Ontario’s universal influenza immunization program with a multi-strain dynamic model. Vaccine [Internet]. 2014;32(39):5098–5117. DOI:10.1016/j.vaccine.2014.06.005
   PubMed Web of Science ®Google Scholar
• Eichner M, Schwehm M, Hain J, et al. 4Flu - an individual based simulation tool to study the effects of quadrivalent vaccination on seasonal influenza in Germany. BMC Infect Dis. 2014;14:365.
   PubMed Web of Science ®Google Scholar
• Ultsch B, Damm O, Beutels P, et al. Methods for health economic evaluation of vaccines and immunization decision frameworks: a consensus framework from a European vaccine economics community. Pharmacoeconomics. 2016;34(3):227–244.
   PubMed Web of Science ®Google Scholar
• Van Maanen BM, De Boer PT, Dolk FCK, et al. Dynamic modelling approaches for the analysis of the cost-effectiveness of seasonal influenza control. Expert Rev Vaccines. 2016;16(1):1–4.
   PubMed Web of Science ®Google Scholar
• Reed C, Meltzer MI, Finelli L, et al. Public health impact of including two lineages of influenza B in a quadrivalent seasonal influenza vaccine. Vaccine. 2012;30(11):1993–1998.
   PubMed Web of Science ®Google Scholar
• Tricco AC, Chit A, Soobiah C, et al. Comparing influenza vaccine efficacy against mismatched and matched strains: a systematic review and meta-analysis. BMC Med. 2013;11:153.
   PubMed Web of Science ®Google Scholar
• DiazGranados CA, Denis M, Plotkin S. Seasonal influenza vaccine efficacy and its determinants in children and non-elderly adults: a systematic review with meta-analyses of controlled trials. Vaccine. 2012;31(1):49–57.
   PubMed Web of Science ®Google Scholar
• Rawlins M, Barnett D, Stevens A. Pharmacoeconomics: NICE’s approach to decision-making. Br J Clin Pharmacol. 2010;70(3):346–349.
   PubMed Web of Science ®Google Scholar
• Marseille E, Larson B, Kazi DS, et al. Thresholds for the cost-effectiveness of interventions: alternative approaches. Bull World Health Organ. 2015;93(October 2014):118–124.
   PubMed Web of Science ®Google Scholar
• Pitman R, Fisman D, Zaric GS, et al. Dynamic transmission modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force Working Group-5. Med Decis Mak. 2012;32(5):712–721.
   PubMed Web of Science ®Google Scholar
• Hodgson D, Baguelin M, Van Leeuwen E, et al. Effect of mass paediatric influenza vaccination on existing influenza vaccination programmes in England and Wales: a modelling and cost-effectiveness analysis. Lancet Public Heal. [Internet]. 2017;6(16):1–8. Available from: http://linkinghub.elsevier.com/retrieve/pii/S2468266716300445
   Google Scholar
• Weidemann F, Remschmidt C, Buda S, et al. Is the impact of childhood influenza vaccination less than expected: a transmission modelling study. BMC Infect Dis [Internet]. 2017;17(1):258. DOI:10.1186/s12879-017-2344-6
   PubMed Web of Science ®Google Scholar
• Skowronski DM, Janjua NZ, Sabaiduc S, et al. Influenza A/subtype and B/lineage effectiveness estimates for the 2011-2012 trivalent vaccine: cross-season and cross-lineage protection with unchanged vaccine. J Infect Dis. 2014;210(1):126–137.
   PubMed Web of Science ®Google Scholar
• McLean HQ, Thompson MG, Sundaram ME, et al. Influenza vaccine effectiveness in the United States during 2012-2013: variable protection by age and virus type. J Infect Dis. 2015;211(10):1529–1540.
   PubMed Web of Science ®Google Scholar
• Lee J, Boutz DR, Chromikova V, et al. Molecular-level analysis of the serum antibody repertoire in young adults before and after seasonal influenza vaccination. Nat Med [Internet]. 2016 November;22:1456–1464. Available from: http://www.nature.com/doifinder/10.1038/nm.4224
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. VFC CDC vaccine price list archives [Internet]. (2017). Available from: https://www.cdc.gov/vaccines/programs/vfc/awardees/vaccine-management/price-list/archive.html.
   Google Scholar
• Heikkinen T, Ikonen N, Ziegler T. Impact of influenza B lineage-level mismatch between trivalent seasonal influenza vaccines and circulating viruses, 1999-2012. Clin Infect Dis. 2014;59(11):1519–1524.
   PubMed Web of Science ®Google Scholar
• Mosnier A, Caini S, Daviaud I, et al. Clinical characteristics are similar across type A and B influenza virus infections. Plos One. 2015;10(9):1–13.
   Web of Science ®Google Scholar
• Tafalla M, Buijssen M, Geets R, et al. A comprehensive review of the epidemiology and disease burden of influenza B in 9 European countries. Hum Vaccin Immunother [Internet]. 2016;12(4):993–1002. DOI:10.1080/21645515.2015.1111494
   PubMed Web of Science ®Google Scholar
• Kissling E, Nunes B, Robertson C, et al. I-­ move multicentre case – control study 2010/11 to 2014/15: is there within ­ season waning of influenza type/subtype vaccine effectiveness with increasing time since vaccination? Euro Surv. 2016;21:16.
   Google Scholar
• Vynnycky E, Pitman R, Siddiqui R, et al. Estimating the impact of childhood influenza vaccination programmes in England and Wales. Vaccine. 2008;26(41):5321–5330.
   PubMed Web of Science ®Google Scholar
• Nyirenda M, Omori R, Tessmer HL, et al. Estimating the lineage dynamics of human influenza B viruses. Plos One. 2016;11(11):1–14.
   Web of Science ®Google Scholar
• Wiersma L, Rimmelzwaan G, De Vries R. Developing universal influenza vaccines: hitting the nail, not just on the head. Vaccines. 2015;3:239–262.
   Web of Science ®Google Scholar
• Van De Sandt CE, Bodewes R, Rimmelzwaan GF, et al. Influenza B viruses: not to be discounted. Future Microbiol. 2015;10(9):1447–1465.
   PubMed Web of Science ®Google Scholar
• Mosterín Höpping A, Fonville JM, Russell CA, et al. Influenza B vaccine lineage selection - an optimized trivalent vaccine. Vaccine [Internet]. 2016;34(13):1617–1622. DOI:10.1016/j.vaccine.2016.01.042
   PubMed Web of Science ®Google Scholar
• Van Hoek AJ, Underwood A, Jit M, et al. The impact of pandemic influenza H1N1 on health-related quality of life: a prospective population-based study. Plos One. 2011;6(3):1–6.
   Web of Science ®Google Scholar
• Damm O, Scholz S, Ultsch B, et al. A systematic review of utility weights for influenza and influenza-like illness. Value Heal. 2016;19(7):A419.
   PubMed Web of Science ®Google Scholar
• Hollmann M, Garin O, Galante M, et al. Impact of influenza on health-related quality of life among confirmed (H1N1)2009 patients. Plos One. 2013;8(3):1–10.
   Web of Science ®Google Scholar
• Hayward AC, Fragaszy EB, Bermingham A, et al. Comparative community burden and severity of seasonal and pandemic influenza: results of the Flu Watch cohort study. Lancet Respir Med [Internet]. 2014;2(6):445–454. DOI:10.1016/S2213-2600(14)70034-7
   PubMed Web of Science ®Google Scholar
• De Boer PT, Frederix GWJ, Feenstra TL, et al. Unremarked or unperformed? Systematic review on reporting of validation efforts of health economic decision models in seasonal influenza and early breast cancer. Pharmacoeconomics. 2016;34(9):833–845.
   PubMed Web of Science ®Google Scholar
• Milne GJ, Halder N, Kelso JK, et al. Trivalent and quadrivalent influenza vaccination effectiveness in Australia and South Africa: results from a modelling study. Influenza Other Respi Viruses. 2016;10(4):324–332.
   PubMed Web of Science ®Google Scholar
• Tetsutani K, Ishii KJ. Adjuvants in influenza vaccines. Vaccine [Internet]. 2012;30(52):7658–7661. DOI:10.1016/j.vaccine.2012.10.007
   PubMed Web of Science ®Google Scholar
• Falsey AR, Treanor JJ, Tornieporth N, et al. Randomized, double-blind controlled phase 3 trial comparing the immunogenicity of high-dose and standard-dose influenza vaccine in adults 65 years of age and older. J Infect Dis [Internet]. 2009;200(2):172–180. Available from: http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/175/CN-00719175/frame.html
   PubMed Web of Science ®Google Scholar
• Barberis I, Myles P, Ault SK, et al. History and evolution of influenza control through vaccination: from the first monovalent vaccine to universal vaccines. J Prev Med Hyg. 2016;57(3):E115-E120.
   Google Scholar
• Subramanian R, Graham AL, Grenfell BT, et al. Universal or specific? A modeling-based comparison of broad-spectrum influenza vaccines against conventional, strain-matched vaccines. PLOS Comput Biol [Internet]. 2016;12(12):e1005204. doi: 10.1371/journal.pcbi.1005204
   PubMed Web of Science ®Google Scholar